These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28986934)

  • 21. Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction: Are we ready?
    Mason JW
    J Electrocardiol; 2017; 50(6):825-827. PubMed ID: 28919218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
    Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
    J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introduction to
    Park JS; Jeon JY; Yang JH; Kim MG
    Transl Clin Pharmacol; 2019 Mar; 27(1):12-18. PubMed ID: 32055576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study.
    Vicente J; Zusterzeel R; Johannesen L; Ochoa-Jimenez R; Mason JW; Sanabria C; Kemp S; Sager PT; Patel V; Matta MK; Liu J; Florian J; Garnett C; Stockbridge N; Strauss DG
    Clin Pharmacol Ther; 2019 Apr; 105(4):943-953. PubMed ID: 30447156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.
    Cavero I; Guillon JM; Ballet V; Clements M; Gerbeau JF; Holzgrefe H
    J Pharmacol Toxicol Methods; 2016; 81():21-36. PubMed ID: 27233533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy.
    Li Z; Mirams GR; Yoshinaga T; Ridder BJ; Han X; Chen JE; Stockbridge NL; Wisialowski TA; Damiano B; Severi S; Morissette P; Kowey PR; Holbrook M; Smith G; Rasmusson RL; Liu M; Song Z; Qu Z; Leishman DJ; Steidl-Nichols J; Rodriguez B; Bueno-Orovio A; Zhou X; Passini E; Edwards AG; Morotti S; Ni H; Grandi E; Clancy CE; Vandenberg J; Hill A; Nakamura M; Singer T; Polonchuk L; Greiter-Wilke A; Wang K; Nave S; Fullerton A; Sobie EA; Paci M; Musuamba Tshinanu F; Strauss DG
    Clin Pharmacol Ther; 2020 Jan; 107(1):102-111. PubMed ID: 31709525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.
    Farkas AS; Nattel S
    Drugs; 2010 Mar; 70(5):573-603. PubMed ID: 20329805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
    Vicente J; Johannesen L; Hosseini M; Mason JW; Sager PT; Pueyo E; Strauss DG
    PLoS One; 2016; 11(12):e0163619. PubMed ID: 28036334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
    Pugsley MK; Curtis MJ; Hayes ES
    Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive
    Yoon SH; Lee HL; Jeong DU; Lim KM; Park SJ; Kim KS
    Front Pharmacol; 2023; 14():1220796. PubMed ID: 37649890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti-seizure medication: Levetiracetam case study.
    Delaunois A; Mathy FX; Cornet M; Gryshkova V; Korlowski C; Bonfitto F; Koch J; Schlit AF; Hebeisen S; Passini E; Rodriguez B; Valentin JP
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01059. PubMed ID: 36748725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 2015 focus on preventing drug-induced arrhythmias.
    Bossu A; van der Heyden MA; de Boer TP; Vos MA
    Expert Rev Cardiovasc Ther; 2016; 14(2):245-53. PubMed ID: 26560188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium.
    Sager PT; Gintant G; Turner JR; Pettit S; Stockbridge N
    Am Heart J; 2014 Mar; 167(3):292-300. PubMed ID: 24576511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
    Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model.
    Han X; Samieegohar M; Ridder BJ; Wu WW; Randolph A; Tran P; Sheng J; Stoelzle-Feix S; Brinkwirth N; Rotordam MG; Becker N; Friis S; Rapedius M; Goetze TA; Strassmaier T; Okeyo G; Kramer J; Kuryshev Y; Wu C; Strauss DG; Li Z
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106890. PubMed ID: 32574700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach.
    Li Z; Garnett C; Strauss DG
    CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):371-379. PubMed ID: 31044559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes.
    Pfeiffer ER; Vega R; McDonough PM; Price JH; Whittaker R
    J Pharmacol Toxicol Methods; 2016; 81():263-73. PubMed ID: 27095424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.
    Ligneau X; Shah RR; Berrebi-Bertrand I; Mirams GR; Robert P; Landais L; Maison-Blanche P; Faivre JF; Lecomte JM; Schwartz JC
    Br J Pharmacol; 2017 Dec; 174(23):4449-4463. PubMed ID: 28941245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.